Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose of this study is to select the optimal formulation of the norovirus vaccine from different concentrations of virus-like particles (VLP), Aluminum Hydroxide and MPL adjuvant (3-O-desacyl-4\'-monophosphoryl lipid A) for further development.
Epistemonikos ID: 542c3a7fb5d23a808dfd25105936d9efe1cbf906
First added on: May 11, 2024